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ABSTRACT
The development and function of the vertebrate nervous
system depend on specific interactions between different
cell types. Two examples of such interactions are synaptic
transmission and myelination. LGI1-4 (leucine-rich glioma
inactivated proteins) play important roles in these processes.
They are secreted proteins consisting of an LRR (leucine-
rich repeat) domain and a so-called epilepsy-associated or
EPTP (epitempin) domain. Both domains are thought to func-
tion in protein–protein interactions. The first LGI gene to
be identified, LGI1, was found at a chromosomal translo-
cation breakpoint in a glioma cell line. It was subsequently
found mutated in ADLTE (autosomal dominant lateral tem-
poral (lobe) epilepsy) also referred to as ADPEAF (autosomal
dominant partial epilepsy with auditory features). LGI1 pro-
tein appears to act at synapses and antibodies against LGI1
may cause the autoimmune disorder limbic encephalitis. A
similar function in synaptic remodelling has been suggested
for LGI2, which is mutated in canine Benign Familial Juve-
nile Epilepsy. LGI4 is required for proliferation of glia in the
peripheral nervous system and binds to a neuronal receptor,
ADAM22, to foster ensheathment and myelination of axons
by Schwann cells. Thus, LGI proteins play crucial roles in ner-
vous system development and function and their study is
highly important, both to understand their biological func-
tions and for their therapeutic potential. Here, we review
our current knowledge about this important family of pro-
teins, and the progress made towards understanding their
functions.
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CELL–CELL INTERACTIONS IN NERVOUS
SYSTEM DEVELOPMENT
Synapse formation and maturation require multiple inter-
actions between presynaptic and postsynaptic neurons that
are mediated by a diverse set of synaptic proteins (Han and
Kim, 2008; McMahon and Diaz, 2011; Siddiqui and Craig,
2011). Initial synapse formation needs both the binding of
secreted proteins to presynaptic and postsynaptic receptors,
and the direct binding between presynaptic and postsynaptic
transmembrane proteins. Many synaptogenic proteins have
been described, some of which, like the secreted LGI proteins
discussed here, are specific to vertebrates.
Myelination also requires cell–cell interactions; myelin is
required for rapid axonal transmission of electrical signals in
the vertebrate nervous system. It consists of multiple wraps
of membrane that permit saltatory conduction between spe-
cialized structures, the nodes of Ranvier. Myelination requires
reciprocal interactions between the axon and oligodendro-
cytes in the CNS (central nervous system) or Schwann cells in
the PNS (peripheral nervous system); reviewed in (Nave, 2010;
Piaton et al., 2010; Quintes et al., 2010). As described below,
LGI4 participates in axon-Schwann cell communication; it
is crucial for PNS (but not CNS) myelination. In addition to
synaptogenesis and myelination, LGI proteins are likely to
participate in other cell–cell interactions as well. The study
of this interesting family of proteins is critical for under-
standing proper development and function of the vertebrate
nervous system, and for gaining insights into therapies for
diseases that affect them.
IDENTIFICATION OF THE LGI FAMILY
As suggested by its name, leucine-rich glioma inactivated, the
LGI protein family was discovered in gliomas. Loss of one copy
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of chromosome 10 is a common event in high-grade gliomas.
In a search for genes that are mutated in these gliomas, Cow-
ell and colleagues identified a gene in the 10q24 region that
was rearranged as a result of a t(10;19)(q24;q13) balanced
translocation in a T98G glioblastoma multiforme cell line
(Chernova et al., 1998). They suggested that the complete loss
of this gene, which contains four LRRs (leucine-rich repeats),
contributes to the malignant progression of glial tumours.
A completely independent line of inquiry implicated LGI1
in epilepsy. Epilepsy is a heterogeneous disease, and families
with multiple epileptic individuals are important resources
for identifying susceptibility genes. In one such family
multiple individuals presented with partial seizures with
auditory features, thereby permitting a susceptibility gene
to be mapped to a 10-centimorgan region of chromosome
10 (Ottman et al., 1995). This type of epilepsy was named
ADPEAF (autosomal dominant partial epilepsy with auditory
features) (Winawer et al., 2000), and additional families with
similar symptoms confirmed linkage to the same region of
chromosome 10 (Winawer et al., 2002). Independently, a
large five-generation Basque family with similar dominant
partial epilepsy also demonstrated linkage to chromosome
10q (Poza et al., 1999). This inherited epilepsy was named
ADLTE [autosomal dominant lateral temporal (lobe) epilepsy].
Making the assumption that the same gene was mutated
in these two families reduced the chromosomal region
containing the epilepsy gene to a 4.2 Mb sequence. All
genes within this region were sequenced in three affected
individuals of three different families revealing distinct
mutations in the LGI1 gene. Extending the analysis to two
additional families revealed two more mutations (Kalachikov
et al., 2002). Independently, Morante-Redolat et al. (2002)
identified mutations in the LGI1 gene in two families. Since
these initial publications many more mutations in the LGI1
gene have been found in ADLTE/ADPEAF patients and the
total number is now 33 (see Ho et al., 2012). The terms ADLTE
and ADPEAF refer to the same clinical entity (OMIM 600512).
In this review, we use the nomenclature of Winawer et al.
(2000) and refer to the disease as ADPEAF. As we discuss
here, LGI1 is associated with synapses in the nervous system
and most recent research has focused on the role of LGI1 in
nervous system function and disease.
The other three LGI family members, LGI2–3 and -4, were
cloned following in silico identification of LGI1-homologous
genes in vertebrate genomes (Gu et al., 2002). Subsequently,
mutations in Lgi2 and Lgi4 demonstrated that these genes
perform important functions in the central and peripheral
nervous systems.
EVOLUTION OF LGI GENES
LGI genes appeared in chordates [Branchiostoma floridae
(amphioxus) has one LGI gene] and are found in all vertebrate
genomes that have been examined to date. Early vertebrate
genomes underwent two rounds of whole genome duplica-
tion (Ohno, 1970; Dehal and Boore, 2005) and presumably
a single primordial LGI gene gave rise to four LGI genes. A
third whole genome duplication occurred in the teleost fish
lineage after the tetrapod-teleost split (Gillis et al., 2009;
Van de Peer et al., 2009; Manning and Scheeff, 2010). The
zebrafish, Danio rerio, a teleost, possesses two copies of lgi1
(lgi1a and lgi1b), two copies of lgi2 (lgi2a and lgi2b), a single
copy of lgi3 and no copy of lgi4 (Gu et al., 2005b). A sim-
ilar picture – with duplicated lgi1 and lgi2 genes, a single
lgi3 gene and no lgi4 gene – emerges from the genomes of
other teleost fishes such as cod, stickleback and platyfish (see
the webpage of Ensembl.org). Following whole genome du-
plication events, gene families often contract, as genes with
redundant functions are lost (Manning and Scheeff, 2010).
In the case of fishes, lgi4 may have been lost as one or more
other LGI genes assumed its functions in peripheral nerve
development. Alternatively, lgi4 diverged from an ancestral
LGI gene specifically in the tetrapod lineage. Coelacanths
(Latimeria sp.) are an order of fish that diverged from teleost
fishes prior to their third genome duplication and are thus
more closely related to the ancestors of the tetrapods. The
coelacanth genome (Amemiya et al., 2013) contains single
copies of lgi1, lgi2, and lgi3 genes, but not lgi4. Surprisingly,
the recently sequenced Xenopus tropicalis genome (Hellsten
et al., 2010) has been found to contain lgi1, lgi2 and lgi4,
but not lgi3. Although it remains to be seen if the absence of
individual LGI genes in coelacanth and frog genomes is real,
the current genome sequence data support the appearance
of Lgi4 in tetrapods. As more genomes are sequenced, the
pattern of LGI gene evolution will become clearer.
STRUCTURE OF LGI PROTEINS
All LGI family members have a calculated molecular mass of
approximately 60 kDa (Chernova et al., 1998) and contain a
signal peptide that is cleaved off, an LRR domain containing
four LRR repeats flanked by cysteine-rich sequences (Kobe
and Kajava, 2001) and an EPTP domain consisting of seven
EPTP repeats (Figure 1A) (Scheel et al., 2002; Staub et al.,
2002). The EPTP repeats most likely fold into a so-called seven
bladed β-propeller, a structure that resembles a slightly con-
ical doughnut. Both the LRR domain and the β-propeller
structure provide a scaffold for specific protein interactions
and are found in a wide range of proteins with diverse phys-
iological function (Buchanan and Gay, 1996; Paoli, 2001b),
but only a handful of LGI protein binding partners have been
identified (see below). Some of these proteins interact with all
LGI proteins, whereas others bind more selectively (O¨zkaynak
et al., 2010; Thomas et al., 2010) and (E. Aunin, unpublished
work). These proteins will be discussed in the context of the
individual LGI proteins to which they bind.
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Figure 1 Structural characteristics of the LGI protein family
In (A), the general domain structure of the LGI protein family is depicted. All LGI proteins have an SP (signal peptide) that is cleaved
off (arrow in A) and is not included in the putative protein structures shown in (B). The glycosylation site present in all LGI members is
indicated in (A) with a branched line structure. The putative structures of the LRR domain and EPTP domain were predicted separately
using the HHpred tool (http://toolkit.tuebingen.mpg.de/hhpred) and the WDR5 protein structure (PDB 2GNQA) as template. Structures
were visualized using the Accelrys Discovery Studio visualizer. The structure is colour-coded from N-terminus (blue) to C-terminus (red)
and corresponds with the colour code in (A). The colour-code graphically reveals the Velcro β-strand (blue) interacting with the last
β-strand (red) of the seventh EPTP module to zip up the EPTP domain structure. How the LRR domain and the EPTP domain are oriented
towards each other is unknown. The stippled black line does not represent any structural feature but is only intended to show the linkage
between the two domains.
The LGI proteins’ LRR domain is most homologous to
Slit proteins (Krex et al., 2002). Slit proteins are large se-
creted proteins involved in axonal guidance and neuronal
migration through interaction with their receptor Round-
about (Robo). The Slit proteins contain four LRR domains,
D1–D4, and each domain is approximately 31–33% homol-
ogous to the LGI LRR domain. A model of the LGI1 LRR do-
main (Leonardi et al., 2011), based on the structure of Slit
LRRs, suggests that it consists of four 24 amino acid long
LRRs. The intron–exon structure of LGI genes further cor-
roborates this conjecture as the repeats are encoded by four
72 nt long exons (exon 2 to 5). The LRRs with the N- and
C-terminal flanking sequences form a slightly curved struc-
ture with parallel β-strands forming the concave face of the
domain (Figure 1B). As Slit proteins dimerize (Howitt et al.,
2004), one hypothesized function of the LRR domain is dimer-
ization. Indeed, LGI1 is secreted as an oligomer (Fukata et al.,
2006) raising the possibility that the LGI proteins homo- or
heterodimerize with other LGI proteins or possibly with other
LRR-containing proteins.
The EPTP domain comprises the C-terminal three/fifths of
LGI proteins. The name Epitempin derives from the obser-
vation that this domain is found in two epilepsy-associated
proteins, LGI1 and GPR98/VLGR/MASS, the latter a trans-
membrane protein mutated in human and mouse audi-
tory epilepsy (Skradski et al., 2001; Nakayama et al., 2002;
McMillan and White, 2004). This name is a bit misleading
as LGI3 and -4, and the deafness-associated protein TSPEAR
(Delmaghani et al., 2012), also contain EPTP repeats but have
not yet been associated with epilepsy. Notably, mutations in
the EPTP-encoding genes LGI1, GPR98 and TSPEAR all pro-
duce auditory symptoms, either noise-induced seizures or
deafness. As mentioned, the EPTP repeats of LGI proteins
likely form a seven bladed β-propeller domain (Scheel et al.,
2002; Staub et al., 2002). The β-propeller domain consists
of four to ten modules (the blades), and is found in a wide
variety of proteins in both prokaryotes and eukaryotes (Fulop
and Jones, 1999; Jawad and Paoli, 2002; Pons et al., 2003;
Chaudhuri et al., 2008). Each β-propeller module consists of
four antiparallel β-strands that form a sheet warped like a
propeller blade (see Figure 1B). In the case of the EPTP do-
main, seven of these modules associate to form a disc with a
conical central pore, and stabilized by hydrophobic interac-
tions between the blades (see Figure 1B). Sites for interactions
with other proteins reside on the outer surfaces, and for some
β-propellers, the pore contains a substrate-binding site, but
whether or not anything associates with the central pore of
LGI proteins is unknown.
Recently, in silico model(s) of the LGI1 EPTP domain have
been published, based on the structure of the β-propeller pro-
tein WDR5 (Limviphuvadh et al., 2010; Leonardi et al., 2011).
A notable feature of the WDR5 structure is that the seven
C© 2013 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) 169
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
L. Kegel and others
clusters of four β-strands, seen in the primary sequence,
are out of register with the seven blades in the structure
(reviewed in Fulop and Jones, 1999; Xu and Min, 2011). Ac-
cordingly, the register of β-strands in the in silico model of
LGI1 structure proposed by Leonardi et al. (2011) is shifted by
one β-strand relative to the boundaries of each EPTP repeat
that were described initially (Scheel et al., 2002; Staub et al.,
2002). A characteristic of β-propeller domains with six or
more repeats is the presence of a ‘Velcro’ or ‘molecular clasp’,
sequence that holds the circular structure closed (reviewed
in Paoli, 2001a). These Velcro sequences consist of one or
more β-strands contributed by one terminal repeat module
that are integrated into the β-sheet formed by the repeat
at the other end, permitting inter-β-strand interactions to
pull the entire β-propeller closed, thereby stabilizing its circu-
lar structure. Leonardi and colleagues propose that for LGI1,
the N-terminal EPTP β-strand resides at the outside of the
C-terminal β-propeller, with the C-terminal β-strand nested
inside it (Figure 1B). The Leonardi model provides a plausible
explanation for the deleterious phenotype of the 1639insA
mutation in one family of ADPEAF patients (Kalachikov et al.,
2002), and the LGI2 truncation seen in BJFE dogs (Seppa¨la¨
et al., 2011). These mutations replace or remove the 11 C-
terminal amino acids of LGI1 or LGI2, respectively. Their ab-
sence may preclude formation of the first EPTP domain, and
preclude folding of the entire β-propeller structure.
How the LRR and EPTP domains of LGI proteins are ori-
ented relative to one another is not known. Currently, this
important question cannot be answered by modelling alone.
The crystal structure of an intact LGI protein is needed to
provide insight into the specific functions of the four LGI
proteins, and to provide better understanding of the effects
of the different human LGI1 mutations.
POST-TRANSLATIONAL MODIFICATION
AND SECRETION OF LGI PROTEINS
All LGI proteins possess consensusN-linked glycosylation sites
(Figure 1A). Asn192, located within the LRR-CT (C-terminal
portion of the LRR) domain, resides in a glycosylation site that
is conserved among all LGI members (Figure 1). Asn277 is part
of a glycosylation site in some LGI1 and LGI2 orthologues, and
a glycosylation site that includes Asn422 is found only inmam-
malian LGI1 proteins. These sites have been demonstrated to
be glycosylated in LGI1 (Sirerol-Piquer et al., 2006). A triple
glycosylation mutant of LGI1 is not secreted and secretion of
the N192Q mutant is severely diminished, underscoring the
importance of these glycosylation sites for normal matura-
tion and secretion of LGI1. LGI4 is glycosylated at the LRR-CT
site (Bermingham et al., 2006), but the functional signifi-
cance of this is unknown. Based on the observations with
LGI1, it is reasonable to postulate that LGI proteins require
glycosylation for one or more steps in their secretion.
Most ADPEAF mutations inhibit LGI1 secretion (de Belles-
cize et al., 2009; Di Bonaventura et al., 2011; Striano et al.,
2011); see Table 1 in (Nobile et al., 2009). Many of these
appear to alter the ability of the LRR domain or the EPTP
domain to fold properly, thereby inhibiting their secretion.
Accordingly, these mutations have provided limited infor-
mation about the functional interactions of LGI1 protein.
However, one ADPEAF mutation, Arg407Cys is secreted nor-
mally (Striano et al., 2011). Rather than affecting LGI1 protein
stability or secretion, this mutation may alter a functionally
significant interaction domain for LGI1, and provides a proof
of principle for utilizing LGI1 structural information to design
mutations that will inform us about LGI1 function.
LGI1 MUTATIONS IN ADPEAF
Asmentioned earlier, LGI1mutations result in ADPEAF (OMIM
600512) (Kalachikov et al., 2002). ADPEAF patients present
with complex partial and secondarily generalized seizures
that are often associated with auditory auras (Nobile et al.,
2009; Michelucci et al., 2013). The average age of seizure
onset is in early adulthood (Winawer et al., 2000) and sub-
tle abnormalities have been observed by magnetic resonance
imaging from ADPEAF patients (Kobayashi et al., 2003; Tessa
et al., 2007). This suggests that ADPEAF results from defects
in brain development, which is consistent with the hypoth-
esized functions for LGI1. ADPEAF mutations have begun to
be examined in the context of other neurological diseases.
LGI1 mutations do not appear to affect depression indepen-
dently of epilepsy (Heiman et al., 2010). The LGI1 mutation
in one ADPEAF family has been correlated with hyperactivity
(Berghuis et al., 2013), and it will be important to determine if
LGI1 mutations impact other diseases of synaptic connectiv-
ity. To date, 33 mutations at 29 distinct locations have been
identified in LGI1 with an average penetrance of approxi-
mately 67% (Rosanoff and Ottman, 2008; Nobile et al., 2009;
Kawamata et al., 2010; Michelucci et al., 2013) (Figure 2).
Not all ADPEAF patients possess mutations in LGI1; the pene-
trance of ADPEAF in families that segregate LGI1 mutations is
higher than in ADPEAF families without LGI1 mutations
(Michelucci et al., 2013), suggesting that the disease has a
complex and heterogeneous pattern of inheritance.
The dominant LGI1 mutations in ADPEAF could be ei-
ther haploinsufficient (one wild-type copy makes insufficient
amounts of protein for proper function) or dominant neg-
ative (i.e. mutant LGI1 interferes with wild-type LGI1 or its
binding partners). The incomplete penetrance of many AD-
PEAF mutations, and the instability and/or inability to be
secreted of many LGI1 proteins resulting from them sug-
gests that these mutations are haploinsufficient (Senechal
et al., 2005; Sirerol-Piquer, 2006). However, the observa-
tion that LGI proteins multimerize (Fukata et al., 2006) sug-
gests a potential for some LGI1 mutations to exert dominant
negative effects. Futhermore, overexpression of a truncated
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Figure 2 A schematic diagram of human LGI1 protein
In this ‘exploded’ view of LGI1, the individual LRR and EPTP modules are separated from one another; dashed lines connect amino
acids that are linked in the intact protein. Amino acids are represented as filled, shaded or open circles, depending on their level of
conservation. The bottom half of circles for amino acids that are changed by point mutations are coloured orange; all of these mutations
are from human except for the mutation at Leu385, which is from rat. For simplicity, frameshift mutations are omitted, with the exception
of one at the C-terminus that provides evidence that the ‘Velcro’ model of β-propeller closure, in which the N-terminal β-strand is
included in the seventh EPTP propeller fold. Human LGI1 mutations were obtained from (de Bellescize et al., 2009; Nobile et al., 2009;
Di Bonaventura et al., 2011; Ho et al., 2012) and the rat mutation from (Baulac et al., 2012). For the EPTP domain, the β-propeller
blades, which in large part would intersect the plane of the figure in the intact protein, have been laid flat. β-strands are outlined by
yellow arrows (Leonardi et al., 2011). Disulfide bonds are depicted as solid lines, and glycosylation sites have a branched line structure.
Boundaries of the eight LGI1 exons are presented as lines through the sequence, with the relevant exon numbers juxtaposed. Every
100th amino acid is labelled.
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Table 1 Potential binding partners of Lgi proteins
Proteins whose association with LGI proteins have been tested directly by co-immunoprecipitation or by co-localization of tagged proteins in cultured cells, are
shown. References are abbreviated as follows: F06 (Fukata et al., 2006); F10 (Fukata et al., 2010); K (Kim et al., 2012); N (Nishino et al., 2010); Ok (Okabayashi and
Kimura, 2010); Oz (O¨zkaynak et al., 2010); P (Park et al., 2008); Sa08 (Sagane et al., 2008); Sa10 (Sagane et al., 2010); Sp (Seppa¨la¨ et al., 2011); T (Thomas et al.,
2010); W (Owuor et al., 2009). In addition, LGI1 has been shown not to bind to ADAM12 (W), ROBO2 (F06), Stargazin (F06), NGR2(T), NGR3(T), and Kv1.1(F10).
ADAM9 does not bind to LGI1 (F06, F10) or to LGI4 (N).
Binding partner Lgi1 Lgi2 Lgi3 Lgi4
ADAM11 Weak (Sa08) Binds (Oz) Does not bind (Oz) Moderate (Sa08)
Binds (W, F10) Binds (Oz, N)
ADAM22 Moderate (Sa08) Does not bind (Oz) Binds (Oz) Strong (Sa08, Sa10)
Binds (T, W, F06; F10) Binds (Sp) Does not bind (F10) Binds (Oz, N)
ADAM23 Strong (Sa08) Does not bind (Oz) Binds (O) Strong (Sa08)
Binds (T, W, F06, F10) Binds (Sp) Binds (K) Binds (Oz, N)
FLOTILLIN1 ND ND Binds (Ok) ND
SYNTAXIN1 ND ND Binds (P) ND
NGR1 Binds (T) ND ND ND
LGI1 (835delC, which corresponds to a truncation of the C-
terminus of the LRR-CT and the entire EPTP domain) inhibited
dendritic pruning in vivo, suggesting that this ADPEAF mu-
tation has a dominant negative effect (Zhou et al., 2009).
Some of the potential dominant negative effects may be
attributable to endoplasmic reticulum stress and activation
of the unfolded protein response, similar to what has been
observed elsewhere (D’Antonio et al., 2013; Li et al., 2013;
Roussel et al., 2013). Curiously, LGI1 was identified in a screen
for genes with monoallelic expression (Wang et al., 2010),
suggesting that such expression may explain the incomplete
penetrance of some ADPEAF mutations, or the haploinsuf-
ficiency of others. Multiple mechanisms may produce the
dominant phenotype of LGI1 mutations.
LGI1 PROTEIN INTERACTIONS IN THE CNS
All LGIs seem to interact with select members of the ADAM
(A Disintegrin And Metalloprotease) transmembrane protein
family (Table 1). More than 40 ADAMs have been identified in
species from Caenorhabditis elegans to human. Some mem-
bers are catalytically active metalloproteases and control cell
signalling by activating membrane-bound growth factors or
by shedding the ectodomain of cell-surface receptors (Seals
and Courtneidge, 2003; Blobel, 2005). Other members are in-
active and are thought to be involved in protein interactions,
especially with integrins (D’Abaco et al., 2006). LGI1 binds to
the extracellular domain of ADAM22, which binds to the third
PDZ domain of PSD-95 through its cytoplasmic C-terminal
ETSI-motif (Fukata et al., 2006). The first two PDZ domains
of PSD-95 in turn bind to the C-terminal tail of stargazin,
a transmembrane regulatory subunit of AMPA (α-amino-3-
hydroxy-5-methylisoxazole-4-propionic acid)-receptors that
is critical for AMPA-receptor trafficking and gating (Chen
et al., 2000; Tomita et al., 2005; Nicoll et al., 2006; Yokoi
et al., 2012). In addition to the stargazin/AMPA receptor
complex, Fukata’s group found that PSD-95 strongly asso-
ciated with LGI1 and ADAM22 in rat brain (Fukata et al.,
2006). Thus, PSD-95 may tether two protein complexes,
stargazin/AMPAR and ADAM22/LGI1 (Figure 3A). Since PSD95
together with stargazin controls the number of AMPA recep-
tors at synapses, this association could explain the increase of
synaptic AMPA/NMDA (N-methyl-D-aspartate) ratio in hip-
pocampal slices after incubation with LGI1; it suggests that
LGI1 is an extracellular factor-controlling synaptic strength
at excitatory synapses (Fukata et al., 2006). Additionally, in-
teraction between ADAM23 and LGI1 has been identified
in the brain (Fukata et al., 2010) and on cultured neurons
(Owuor et al., 2009). Both ADAM22 knockout and ADAM23
knockout mice show strong overlap in phenotype with LGI1
knockout mice, which is characterized by severe spontaneous
epilepsy and premature death (Sagane et al., 2005; Owuor
et al., 2009; Chabrol et al., 2010; Fukata et al., 2010; Yu et al.,
2010). Additionally, a point mutation in Adam23 has been
found in epileptic Belgian Shepherd dogs (Seppa¨la¨ et al.,
2012). Importantly, ADAM22 and ADAM23 co-assemble in
the brain dependent on LGI1 (Fukata et al., 2010). Thus, it
was hypothesized that LGI1 forms a bridge between presy-
naptic ADAM23 and postsynaptic ADAM22 (Fukata et al.,
2010) (Figure 3) effectively regulating trans-synaptic inter-
actions contributing to synaptic strength.
In addition to ADAM22 and ADAM23, LGI1 also binds to
ADAM11 (Sagane et al., 2008), which is an ADAM protein
essential for spatial learning, motor coordination and noci-
ceptive responses (Takahashi et al., 2006a, 2006b). However,
the question whether ADAM11 resides within the same com-
plex with LGI1, ADAM22 and ADAM23 was not addressed and
electro-physiological studies will be needed to determine if
ADAM11 has a role in synaptic transmission and plastic-
ity. Furthermore, the interaction between ADAM23 and LGI1
affects neurite outgrowth. This conclusion is based on the
observation that addition of LGI1 to DRGs or hippocam-
pal neurons causes a dose dependent increase in neurite
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Figure 3 Possible mechanisms by which LGI proteins participate in cell–cell interactions
Panels (A–C) depict several possible mechanisms by which LGI1 controls synapse development and function, and LGI4 controls PNS
development. Note that these mechanisms are not mutually exclusive; the figure simply summarizes what currently is known or
postulated for each interaction. (A) At synapses, LGI1 dimers may form a bridge between post-synaptic ADAM22, which is linked to
the stargazin/AMPAR complex through PSD95 and stargazin, and presynaptic ADAM23 (Fukata et al., 2010). LGI1 has an effect on
Kv1.1 inactivation through mechanisms that are unclear (Fukata et al., 2006). (B) In peripheral glial precursors, LGI4 appears to act
as a paracrine or autocrine factor through binding to ADAM22 (Nishino et al., 2010). (C) During Schwann cell ensheathment and
myelination of axons, LGI4 binds to the disintegrin domain of ADAM22. This interaction could trigger signalling or protein localization
within the axon, thereby activating signal(s) to the Schwann cell. An LGI4–ADAM22–PSD95 interaction could cluster proteins at the
axonal membrane. Alternatively, LGI4 binding to ADAM22 could induce the formation of protein complex(es) extracellularly. LGI4 might
modulate ADAM22–integrin interactions, which also utilize the ADAM22 disintegrin domain (D’Abaco et al., 2006).
outgrowth, and this effect is reduced for neurons cultured
from Adam23 knockout mice (Owuor et al., 2009).
LGI1 protein appears to affect NMDA-receptor subunit
expression. The NMDA receptor (NMDA-R) forms a hetero-
tetramer between two NR1 and two NR2 subunits. A hall-
mark of glutamatergic synapse maturation is the change in
postsynaptic NMDA-R NR2 subunit composition (Barth and
Malenka, 2001; Waites et al., 2005). The NR2B subunit is
mainly expressed in immature neurons of the early postnatal
brain. During development, the number of NR2A subunits
grows, and eventually NR2A subunits outnumber NR2B sub-
units. LGI1 expression in vivo increases when the NR2B/NR2A
ratio decreases, and when mutant ADPEAF LGI1 is overex-
pressed in mice, NR2B/NR2A increases (Zhou et al., 2009).
These observations suggest that LGI1 regulates postsynaptic
function during development. The same study showed that
overexpressed ADPEAF mutant LGI1 blocks the normal devel-
opmental pruning of excess neuronal dendrites, resulting in
an increase of excitatory synaptic transmission and seizure
susceptibility. Both LGI1 and integrins (Chavis andWestbrook,
2001) seem to be crucial to the synchronous maturation of
pre- and postsynaptic membrane functions of glutamatergic
synapses during postnatal development and both bind the
same disintegrin domain of ADAM proteins (Fukata et al.,
2006; Yang et al., 2006). Furthermore, both integrin and
LGI1 regulate NR2 subunit composition via tyrosine kinase
signalling (Chavis and Westbrook, 2001; Zhou et al., 2009).
These observations suggest that LGI1, integrins and ADAM
proteins may cooperate to promote glutamatergic synapse
maturation.
LGI1 also indirectly binds Kv1.1 VGKC (voltage-gated
potassium channels), which is a major constituent of presy-
naptic A-type channels that modulate synaptic transmission
in CNS neurons (Schulte et al., 2006). LGI1 protein expression
was reported to reduce Kv1.1 inactivation via the intracellu-
lar β-subunit of the channel (Schulte et al., 2006). However,
since LGI1 has a signalling sequence and is secreted, it is un-
likely that LGI1 competes with Kvβ1 for binding to Kv1.1. In
contrast to wild-type LGI1 protein, certain mutant LGI pro-
teins that cause ADPEAF in patients could not reduce Kv1.1
inactivation (Schulte et al., 2006). Interestingly, these same
mutant LGI proteins are not secreted (Senechal et al., 2005;
Sirerol-Piquer et al., 2006; Nobile et al., 2009) suggesting
that LGI1 needs to be secreted prior to having an effect on
channel inactivation.
Since the LRR domains of LGI proteins are very homolo-
gous to the Slit proteins, they might have similar functions.
Indeed, LGI1 counteracts myelin-induced growth cone col-
lapse and neurite outgrowth inhibition (Thomas et al., 2010).
LGI1 binds to Nogo receptor 1 (NgR1), raising the possibility
that LGI1 is an antagonist of myelin-based growth inhibitors
(Thomas et al., 2010). ADAM22 resides in a complex with
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NgR1 and facilitates LGI1 binding to this receptor, suggest-
ing that NgR1 and ADAM22 collaborate to create an LGI1
binding complex that is important for synapse formation
(Thomas et al., 2010). It has not been tested whether other
LGI proteins bind any of the Nogo receptors. Together these
observations underscore an important role for LGI1 in brain
excitation and development, explaining why LGI1 mutations
result in epilepsy.
THE ROLE OF LGI1 IN CNS DEVELOPMENT
AND FUNCTION
In the CNS, LGI1 expression patterns are complex. Although
the LGI1 gene is active in the caudal ganglionic eminence
at e13.5 in the mouse (Kusuzawa et al., 2012), it appears to
be expressed primarily postnatally. It is expressed in multi-
ple, discrete locations in adult brain (Kalachikov et al., 2002;
Morante-Redolat et al., 2002; Senechal et al., 2005; Mag-
daleno et al., 2006; Ribeiro et al., 2008; Yu et al., 2010).
Studies using transgenic mice that possess a bacterial arti-
ficial chromosome in which Lgi1 regulatory sequences drive
expression of GFP (green fluorescent protein) have produced
similar results (Head et al., 2007). In these mice, Lgi1-driven
GFP expression is observed in glial cells in some brain regions,
whereas in others, GFP expression was exclusively neuronal.
The observation of Lgi1-driven GFP expression in glial cells of
the midbrain and elsewhere is significant in light of the role
of the midbrain in the propagation of audiogenic seizures
(Garcia-Cairasco et al., 1993; Garcia-Cairasco, 2002; Doretto
et al., 2009). The importance for normal CNS function of LGI1
expression in specific cell types and brain regions remains to
be determined.
Mice and rats that lack Lgi1 die of seizures during the third
postnatal week, showing that normal development or func-
tion of the CNS requires LGI1 (Chabrol et al., 2010; Fukata
et al., 2010; Yu et al., 2010; Baulac et al., 2012). Two of
the three independently created lines of Lgi1 knockout mice
have been subjected to electrophysiological analyses. mEP-
SCs (miniature excitatory postsynaptic currents) result from
the spontaneous release of synaptic vesicles in the absence of
a stimulus; changes in their frequency suggest a presynaptic
defect, whereas changes in their amplitude suggest a post-
synaptic defect. In brain slices from their Lgi1 mutant mice,
Fukata et al. (2010) found a decrease in mEPSC amplitude
but no change in frequency, suggesting that LGI1 functions
postsynaptically. In contrast, Yu et al. (2010) observed an
increase in the frequency of mEPSCs with no differences in
their amplitudes using brain slices from their Lgi1 knockout
mice. Thus, despite the similar seizure phenotypes of their
mouse strains, the groups came to opposite conclusions as
to whether LGI1 acts pre- or postsynaptically. Other electro-
physiological studies on BAC transgenic mice overexpressing
either wild-type Lgi1 or a mutant form that is found in AD-
PEAF, suggest that LGI1 acts both pre- and postsynaptically
(Zhou et al., 2009). The apparent paradox may result from
subtle differences in complicated experimental procedures,
or more interestingly, it might reflect different activities that
occur in vivo. Mice expressing mutant LGI1 also display re-
duced developmental pruning of dendritic arbors of hip-
pocampal granule cells and increased spine density, thereby
increasing neural excitability (Zhou et al., 2009). Similarly, it
was demonstrated recently that LGI1 also regulates the prun-
ing of retinogeniculate fibres (Zhou et al., 2012). These obser-
vations are consistent with increased neuronal outgrowth of
wild-type mouse neurons by Lgi1 (Owuor et al., 2009). Thus,
LGI–ADAM complexes add to a growing list of trans-synaptic
complexes whose precise role in synaptic maturation and
preservation are yet to be elucidated (reviewed in McMahon
and Diaz, 2011; Siddiqui and Craig, 2011).
Lgi1 MUTATIONS IN ZEBRAFISH AND
RATS
Rats and zebrafish with mutations in their LGI1 homologues
are important resources for the development of new treat-
ments for ADPEAF and perhaps other epilepsies as well. Ex-
pression of both homologues of LGI1 in zebrafish, lgi1a and
lgi1b, has been knocked down using antisense morpholinos,
demonstrating that the two genes have acquired distinct
but overlapping developmental functions (Teng et al., 2010,
2011). Low-level inhibition of lgi1a has no effect on fishmor-
phology, but sensitizes them to the seizure-inducing drug PTZ
(pentylenetetrazole). High-level inhibition of lgi1a produces
developmental abnormalities, including reductions in brain,
eyes and tail, presumably due to increased CNS apoptosis;
these fish also display seizure-like hyperactive swimming be-
haviours (Teng et al., 2010). In contrast, lgi1b knockdown fish
display hydrocephalus and heart oedema, but not hyperac-
tivity, yet retain sensitivity to PTZ (Teng et al., 2011). Rats that
carry an ENU (N-ethyl-N-nitrosourea)-generated leucine to
arginine mutation (L385R) in the fourth EPTP domain of LGI1
recapitulate the susceptibility to audiogenic seizures seen in
ADPEAF, and display a similar profile of anti-epileptic drugs
that suppress those seizures (Baulac et al., 2012). The Ze-
brafish lgi1 mutants will permit screens for small molecules
that ameliorate their abnormal phenotypes, whereas the Lgi1
mutant rats will be useful for preclinical testing of candidate
antiepileptic drugs.
LGI1 IN GLIOMAS AND OTHER CANCERS
Although LGI1 was identified initially from chromosomal
breakpoint(s) in high-grade gliomas, and was proposed to
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function as a tumour suppressor gene (Chernova et al., 1998),
its role in oncogenesis remains controversial. LGI1 expression
is reduced or absent in many glioma cell lines (Chernova
et al., 1998; Krex et al., 2002; Rossi et al., 2005); it also
has been reported to be down-regulated in glioma tumours
(Besleaga et al., 2003), in Barrett’s-related adenocarcinoma
of the esophagus (Peng et al., 2008), and in prostate can-
cer (Cowell et al., 2010). LGI1 expression in neuroblastoma
cells inhibits proliferation and causes apoptosis (Gabellini
et al., 2006), further suggesting its anti-oncogenic poten-
tial. In glioma cells, LGI1 re-expression reduces their ability
to proliferate and form colonies on soft agar in one study
(Kunapuli et al., 2003), but not in another (Krex et al., 2002).
In contrast, co-expression of a neuronal marker and LGI1
in gliomas suggests that LGI1 expression levels in these tu-
mours may relate to the number of trapped neurons (Piepoli
et al., 2006), and ADPEAF patients do not show increased fre-
quencies of glioma (Brodtkorb et al., 2003; Gu et al., 2005a).
An important use of Lgi1 knockout mice will be to assess
their susceptibility to tumorigenesis. Additionally, the effect
of LGI1 expression on increasing AKT (protein kinase B) sig-
nalling, reducing ERK (extracellular-signal-regulated kinase)
signalling, and reducing matrix metalloproteinase expression
in glioma and other cells in culture (Kunapuli et al., 2004;
Sirerol-Piquer et al., 2006; Kunapuli et al., 2010) may provide
clues about its function in vivo.
LGI1 AND LIMBIC ENCEPHALITIS
LE (limbic encephalitis) is a neurological autoimmune dis-
ease associated with antibodies against a variety of antigens
(reviewed in Tuzun and Dalmau, 2007; Irani and Vincent,
2011; Vincent et al., 2011). Symptoms include memory loss,
confusion, brain MRI abnormalities and seizures. Recently,
in such patients auto-immune antibodies against LGI1 have
been found (Irani et al., 2010; Lai et al., 2010). As the seizure
susceptibility of LE patients is also observed in ADPEAF pa-
tients and Lgi1 mutant rats and mice, it is reasonable to
assume that at least some of the LE symptoms result from
a reduction in LGI1 levels. Initially, LE was considered rare
and tumour-associated. Currently, it is recognized also in
patients free of tumours, to present with a variety of symp-
toms, and to involve tissues beyond the limbic system. VGKCs
are a common autoimmune antigen in these patients. Anti-
VGKC antibodies typically are detected by their ability to im-
munoprecipitate radio-labelled α-dendrotoxin, a potassium
channel-binding protein, after it is added to lysates of brain
tissue. However, upon further study, it was found that most
of these antibodies reacted with LGI1 and not with potas-
sium channel subunits (Irani et al., 2010; Lai et al., 2010). In
fact, almost 90% of these LE cases possess LGI1-reactive sera.
Some cases of LE are preceded by (a prodrome) or overlap
with faciobrachial dystonic seizures, which are character-
ized by frequent brief seizures that typically affect an arm
and ipsilateral face (Irani et al., 2011). Recognition of these
clinical signs as a prelude to full LE provides a time win-
dow for early therapeutic intervention to limit the severity
of LE symptoms and maybe prevent permanent disability.
These clinical observations confirm that LGI1 is essential for
proper functioning of vertebrate synapses, not only for their
maturation. Epilepsy affects 1% of people worldwide; many
of these cases are idiopathic and may have an autoimmune
aetiology. Therefore the low prevalence of ADPEAF may un-
derstate the importance of LGI1 as an epilepsy gene. Should
pathogenic anti-LGI1 antibodies bind to specific epitopes,
these epitopes could be druggable and lead to effective new
epilepsy treatments.
What can anti-LGI1-mediated LE tell us about LGI1 func-
tion? First, the onset of pathology in LE patients suggests that
LGI1 is required for functioning of fully developed synapses,
in addition to its role in synaptic maturation (Owuor et al.,
2009). The differences between the symptoms of ADPEAF
and LE patients may reflect disruption in both developing and
mature synapses in the former, versus only mature synapses
in the latter. Secondly, faciobrachial dystonia likely involves
the basal ganglia (Irani et al., 2010; Plantone et al., 2013),
suggesting that Lgi1 expression there (Head et al., 2007) is
functionally significant. Thirdly, patient anti-LGI1 antibod-
ies trigger epileptiform activity in hippocampal slices (Lalic
et al., 2011). This experimental model system will help iden-
tify mechanisms by which LGI1 controls synaptic activity.
Fourthly, LE patient LGI1 antibodies may disrupt specific
LGI1 interactions with ADAM proteins or other accessory pro-
teins. Characterization of these interactionswill provide addi-
tional insights into synaptic function. Curiously, one patient’s
serumwas positive for LGI1 immunoreactivity, but negative in
the immunoprecipitation assay for VGKCs, suggesting VGKC-
independent functions for LGI1 (Irani et al., 2010). Thus, the
identification of a connection between LGI1 and LE will ad-
vance both our understanding of synaptic biology, and our
approach towards diagnosis and treatment of epilepsy.
THE ROLE OF LGI2 IN CNS DEVELOPMENT
LGI2 is associated with canine Benign Familial Juvenile
Epilepsy. In the Italian water dog Lagotto Romagnolo, the
disease is transient, generally disappearing by 10 weeks of
age, and could serve as a model for human remitting epilep-
sies. Analysis of a Finnish pedigree of these dogs indicated
a primarily recessive inheritance (Jokinen et al., 2007). Using
an expanded pedigree of these dogs, Seppa¨la¨ and colleagues
identified 11 pairs of discordant siblings (one affected, one
not). Their DNA was subjected to genome-wide association
analysis, revealing a region of homozygosity on canine chro-
mosome 3. Subsequent sequencing revealed that roughly
36% of Lagatto Romagnolo dogs carry a point mutation
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in LGI2 that results in truncation of 11 amino acids from
the C-terminus of the mutant LGI2 protein (Seppa¨la¨ et al.,
2011), indicating that LGI2, like LGI1, is an epilepsy gene.
Structurally, this mutation is adjacent to the frameshift mu-
tation in LGI1 in ADPEAF patients described by Kalachikov
and colleagues (Kalachikov et al., 2002), providing additional
evidence for the requirement of the C-terminal amino acids
of LGI proteins to hold the EPTP domain structure together,
as predicted by the Velcro model of β-propeller folding.
The protein interactions of LGI2 are less well studied than
are those of LGI1. In culture, LGI2 was found to bind to
the cell surface of ADAM11-expressing cells, but not to cells
that expressed either ADAM22 or ADAM23 (O¨zkaynak et al.,
2010). However, a later study in rat brain showed that LGI2
was, like LGI1, co-immunoprecipitated with both ADAM22
and ADAM23 antibodies, suggesting that LGI2 interacts – at
least indirectly – with these ADAM proteins (Seppa¨la¨ et al.,
2011). As mentioned above, a truncating mutation in LGI2
causes benign juvenile epilepsy in dogs. Just like most muta-
tions in LGI1 causes the mutated protein to be retained in the
cell and degraded, this mutation of LGI2 completely abolishes
its secretion (Seppa¨la¨ et al., 2011). These observations sug-
gest that LGI1 and LGI2 function through a similar mecha-
nism that affects synaptic maturation at different time points
of postnatal nervous system development. Importantly, LGI2
expression in the brain is highest preceding axonal pruning
and before the onset of epilepsy, suggesting that LGI2 acts
during the network construction phase (Seppa¨la¨ et al., 2011).
LGI1 might then act during the pruning phase to ensure an
electrically stable network to serve the rest of the animal’s
life, explaining why in LGI2-mutant dogs’ epileptic episodes
are only seen in young animals.
MULTIPLE POTENTIAL FUNCTIONS OF
LGI3
Unlike Lgi1, Lgi2 and Lgi4, mutations in Lgi3 have yet to be
associated with a pathological phenotype in humans or ex-
perimental animals. Mice in which Lgi3 exon1 (including the
initiation codon) has been deleted appear normal (Kim et al.,
2013), although a residual 75 kD isoform suggests the exis-
tence of an alternative start site (Park et al., 2008; Kim et al.,
2013). In vitro experiments using cell lines suggests that LGI3
may perform several distinct functions. Putative LGI3-specific
antibodies co-immunoprecipitate syntaxin1, but not SNAP-
25 or other components of the secretory apparatus (Park
et al., 2008). Curiously, the C-terminus of syntaxin1 is buried
within the plasma membrane, and is inaccessible (Suga et al.,
2003). Therefore its interaction with LGI3 (a) occurs in the cy-
toplasm, (b) is indirect, perhaps mediated by ADAM proteins
or (c) occurs as a result of tissue homogenization. The first
two possibilities are reminiscent of the interaction between
LGI1 and Kvβ1 (Schulte et al., 2006). Amyloid Aβ40 and Aβ42
peptides transiently up-regulate LGI3 expression in astro-
cytes, and LGI3 appears to promote Aβ endocytosis through
an interaction with flotillin1 (Kimura et al., 2007; Okabayashi
and Kimura, 2007, 2008, 2010). Thus LGI3 may mediate en-
docytosis for both syntaxin1 and amyloid peptides.
LGI3 may also function in cell types other than astro-
cytes. LGI3 expression in brain increases postnatally and it is
expressed in neurons but not in oligodendrocytes (Lee et al.,
2006; Okabayashi and Kimura, 2007), but it is enriched in ho-
mogenates of CNS myelin relative to homogenates of whole
brain (Dhaunchak et al., 2010). These observations suggest
that it may function in myelinated nerve fibres. Additionally,
LGI3 induces neurite outgrowth and increases phosphoryla-
tion of the signal transduction proteins Akt and FAK (focal
adhesion kinase) (Park et al., 2010). Keratinocytes express
LGI3, and it may promote their survival following UV irra-
diation (Lee et al., 2012). Multiple neural crest-derived cell
types express Lgi3, including melanoma cell lines (Rossi et al.,
2005), DRG neurons (Bermingham et al., 2006) and adipocytes
(Kim et al., 2012). LGI3 suppresses expression of the adipocyte
hormone adiponectin (Kim et al., 2013), and it attenuates pre-
adipocyte differentiation through binding to Adam23 (Kim
et al., 2012). It is at present unclear what common LGI3-
mediated mechanism might underlie these diverse biologi-
cal functions. Together these observations suggest multiple
functions for LGI3 that await further elucidation by the anal-
ysis of Lgi3 mutant mice.
INVOLVEMENT OF LGI4 IN CELL–CELL
INTERACTIONS IN THE PERIPHERAL
NERVOUS SYSTEM
Cell–cell interactions are required during PNS development
for Schwann cell proliferation, migration, survival and
myelination; however, the molecular mechanisms mediating
these interactions are poorly understood. Study of the claw
paw mutation in mice has revealed a novel LGI4-mediated
signalling pathway that controls peripheral myelination.
In 1977, Nelda Blaisdell, an animal technician handling
C57BL/6-obese mice at The Jackson Laboratory in Bar
Harbor, Maine, noted a litter in which two pups had limb ab-
normalities. Rather than holding their forelimbs up towards
the head as most mouse pups do, they were held out, away
from the body, or lowered towards the thorax. Mating of the
littermates of these affected pups demonstrated that the
phenotype was heritable. The new spontaneous mutation,
called claw paw (clp) caused PNS hypomyelination without
affecting central myelin (Henry et al., 1991). Because of the
similarity in its myelination phenotype with that of mice
lacking the POU domain transcription factor POU3f1/Oct6
(Bermingham et al., 1996; Jaegle et al., 1996), the clp
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mutation was investigated further. However, the clp mu-
tation mapped to a separate locus on chromosome 7, and
initial Oct6 expression was not affected (Darbas et al., 2004;
Bermingham et al., 2006). The clp mutation was positionally
cloned using a series of backcrosses, and found to result
from an insertion in the Lgi4 gene (Bermingham et al.,
2006), demonstrating a critical role for LGI4 in peripheral
myelination.
Claw paw (clp/clp) mice, in which LGI4 is not secreted
(Bermingham et al., 2006), display a delay in radial sorting
of axon fibres, and nerve-grafting experiments demonstrate
that LGI4 function is required in Schwann cells and possi-
bly in neurons (Darbas et al., 2004). LGI4 binds to ADAM22
(Table 1), and Adam22 knockout mice show a similar periph-
eral hypomyelination and forelimb phenotype to claw paw
mice (Sagane et al., 2005; Nishino et al., 2010; O¨zkaynak et al.,
2010); peripheral hypomyelination also is seen following
Schwann cell-specific deletion of Lgi4, and neuron-specific
deletion of Adam22 (O¨zkaynak et al., 2010). Thus, Schwann
cell-secreted LGI4 appears to interact with ADAM22 on pe-
ripheral axons and in this way enable Schwann cell–neuron
communication. The interaction could trigger a reciprocal en-
sheathment and/or myelination signal to Schwann cells (Fig-
ure 3). The nature of these putative signalling components
is unknown. One possibility is that LGI4–ADAM22 modulates
Nrg1 (neuregulin) signalling, but if so, it does not modulate
the surface expression of Nrg1, a major regulator of Schwann
cell migration and myelination (O¨zkaynak et al., 2010). An-
other possibility is that LGI4 modulates an already existing
interaction between ADAM22 and another ADAM22-binding
protein on the Schwann cell membrane, for example inte-
grins (Figure 3). In addition to ADAM22, LGI4 can also bind to
ADAM23 and ADAM11 (Sagane et al., 2008; O¨zkaynak et al.,
2010).Whether these ADAMproteins play a role in PNSmyeli-
nation is at present unknown. It is possible that – in analogy
with the proposed role of LGI1 in regulating trans-synaptic
adhesion (Figure 3) – LGI4 links axons and Schwann cells
through interactions with ADAM22 in the axonal membrane
and ADAM23 or ADAM11 in the Schwann cell membrane.
Lgi4 is expressed initially by neural crest stem cells but
its expression becomes restricted to the glial cells that
derive from them. These neural crest-derived cells include, in
addition to Schwann cells, enteric glial cells with properties
resembling those of astrocytes in CNS, and satellite cells of
(para-) sympathetic and dorsal root ganglia (reviewed in
Jessen, 2004). Analysis of cultures derived from embryonic
enteric and (para-) sympathetic ganglia revealed that LGI4 is
required for proper levels of proliferation of glial precursors,
but not for glial fate determination of neural crest stem
cells (Nishino et al., 2010). Interestingly, embryonic sciatic
nerve Schwann cells proliferated normally in the absence
of LGI4 (Nishino et al., 2010), demonstrating that different
types of PNS glial cells have different requirements for
LGI4. Whether the proliferative effect of LGI4 on these glial
precursors is mediated through an ADAM receptor is an
important unanswered question. Thus, LGI4 has multiple
functions including proliferation of enteric glia and satellite
cells in PNS, and later, myelin formation in Schwann cells.
The requirement for LGI4 for embryonic enteric glial cell
and satellite cell proliferation contrasts with that of LGI1
for glioma cells as LGI1 inhibits proliferation of glioma cells
(Chernova et al., 1998; Krex et al., 2002).
CONCLUDING REMARKS
Over the last decade, LGI proteins have emerged as important
regulators of cellular interactions in the nervous system and
their mutation has been associated with diverse pathologies
such as epilepsy, psychiatric disorders and hypomyelination.
However, their mechanism or mechanisms of action remain a
mystery. Advances in understanding one LGI family member
may inform us about the functions of others. LGI proteins
are secreted proteins, but because most mutations in LGI
proteins affect their secretion, these mutations do not tell
us much about the mechanism of action of LGI proteins. The
disease-associated mutation in LGI1 that appears to affect
its interactions with other proteins rather than its secretion
(Striano et al., 2011) suggests that identification of addi-
tional disease-associated, yet normally secreted, LGI mutant
proteins will help map their functionally relevant interfaces.
Further insight into LGI protein function may come from
studies that map the epitopes within LGI1 recognized by sera
of different LE patients. It is not known at present whether
the sera from different LE patients recognize the same or
different epitopes. Mapping of these epitopes might tell us
how these antibodies interfere with normal LGI1 function
and cause disease. The crystal structure of an LGI protein
will inform us of its overall shape, and how its functionally
significant interfaces are oriented. These studies will provide
a fuller understanding of LGI protein interactions with other
proteins.
All LGI proteins appear to interact with ADAM22/23/11
receptors albeit probably with very different affinities. The
high degree of identity among LGI proteins and their affinity
for these ADAM receptors suggest that they act through a
similar mechanism. However, it is not known whether the LGI
proteins are functionally equivalent or serve distinct func-
tions in different parts of the nervous system at different
developmental stages. The one published experiment that ad-
dresses this issue demonstrated that LGI3 could not replace
LGI1 in CNS synaptic development (Fukata et al., 2010), pos-
sibly due to a much lower affinity of LGI3 for the ADAM22
receptor. An understanding of the functional relationship
of LGI proteins will require the determination of the rela-
tive affinities of these proteins for the ADAM receptors. An-
other open question is how LGI–ADAM interactions influence
ADAM–integrin interactions: Are they mutually exclusive or
does LGI binding potentiate ADAM–integrin interactions?
Answering these questions, in addition to identifying the full
C© 2013 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) 177
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
L. Kegel and others
repertoire of LGI receptors in different parts of the nervous
system will elucidate mechanistic aspects that are common
to the LGI protein family as well as to those that are member
specific.
LGI proteins evolved with vertebrates, but many of the
intercellular interactions in which they function, such as
synapses between neurons, clearly predate them. Are the
biological functions of LGI proteins required in invertebrates,
and if so, what proteins perform them? If LGI proteins per-
form vertebrate-specific functions, could their appearance
have been a crucial step in the evolution of complex verte-
brate nervous systems? As we learn more about what LGI
proteins do, the answers to these questions will become
apparent.
Importantly, we anticipate that ongoing and future clin-
ical, genetic and biochemical work directed towards an un-
derstanding of the biology and pathology of LGI proteins will
ultimately lead to novel approaches in combating the dev-
astating neurological diseases associated with mutations in
the LGI gene family.
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